BioVaxys Technology Corp. Closes Debt Settlement Transaction

(TheNewswire)

VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp.(CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announcesthat, further to its news release dated November 14, 2025, it hasissued 1,792,387 common shares in the capital of the Company (each a“ SettlementShare ”), at a deemed value of $0.23 perSettlement Share, in full and final settlement of accrued andoutstanding indebtedness in the aggregate amount of $412,249 (the“ Debt SettlementTransaction ”).

All securities issued in connection with the DebtSettlement are subject to a statutory hold period of four months fromthe date of issuance in accordance with applicable securitieslegislation

This news release does not constitute an offer to sellor a solicitation of an offer to buy of any securities in the UnitedStates. The securities described herein have not been, and will notbe, registered under the United States Securities Act of 1933, asamended (the “ U.S.Securities Act ”), or any state securitieslaws, and may not be offered or sold within the United States exceptin compliance with the registration requirements of the U.S.Securities Act and applicable state securities laws or pursuant toavailable exemptions therefrom.

About BioVaxys TechnologyCorp.

BioVaxys Technology Corp. ( www.biovaxys.com ), abiopharmaceuticals company registered in British Columbia, Canada, isa clinical-stage biopharmaceutical company dedicated to improvingpatient lives with novel immunotherapies based on the DPX™ immune-educatingtechnology platform and it’s HapTenix© tumorcell construct platform, for treating cancers, infectious disease,antigen desensitization for food allergy, and other immunologicaldiseases. Through a differentiated mechanism of action, the DPX™platform delivers instruction to the immune system to generate aspecific, robust, and persistent immune response. The Company’sclinical stage pipeline includes maveropepimut-S (MVP-S), based on theDPX™ platform, and in Phase IIB clinical development for advancedRelapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinumresistant Ovarian Cancer. MVP-S delivers antigenic peptides fromsurvivin, a well-recognized cancer antigen commonly overexpressed inadvanced cancers, and also delivers an innate immune activator and auniversal CD4 T cell helper peptide. MVP-S has been well tolerated andhas demonstrated defined clinical benefit in multiple cancerindications as well as the activation of a targeted and sustained,survivin-specific anti-tumor immune response. BioVaxys is alsodeveloping DPX™+SurMAGE, a dual-targeted immunotherapy combiningantigenic peptides for both the survivin and MAGE-A9 cancer proteinsto elicit immune responses to these two distinct cancer antigenssimultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPAfor peanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.

BioVaxys common shares are listed on the CSE under the stock symbol “BIOV”and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on theOTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com andconnect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “ James Passin ”

James Passin, Chief Executive Officer

Phone: +1 740 358 0555

Cautionary Statements RegardingForward Looking Information

This news release includes certain“forward-looking information” and “forward-looking statements”(collectively “ forward-looking statements ”) within the meaning of applicablesecurities legislation. All statements, other than statements ofhistorical fact, included herein, without limitation, statementsrelating to the Debt Settlement, are forward looking statements.Forward-looking statements are frequently, but not always, identifiedby words such as “expects”, “anticipates”, “believes”,“intends”, “estimates”, “potential”, “possible”, andsimilar expressions, or statements that events, conditions, or results“will”, “may”, “could”, or “should” occur or beachieved. There can be no assurance that such statements will prove tobe accurate, and actual results and future events could differmaterially from those expressed or implied in such forward-lookingstatements.

Forward-looking statements reflectthe beliefs, opinions and projections on the date the statements aremade and are based upon a number of assumptions and estimates,primarily the assumption that BioVaxys will be successful indeveloping and testing vaccines, that, while considered reasonable byBioVaxys, are inherently subject to significant business, economic,competitive, political and social uncertainties and contingenciesincluding, primarily but without limitation, the risk that BioVaxys’vaccines will not prove to be effective and/ or will not receive therequired regulatory approvals. With regards to BioVaxys’ business,there are a number of risks that could affect the development of itsbiotechnology products, including, without limitation, the need foradditional capital to fund clinical trials, its lack of operatinghistory, uncertainty about whether its products will complete thelong, complex and expensive clinical trial and regulatory approvalprocess for approval of new drugs necessary for marketing approval,uncertainty about whether its autologous cell vaccine immunotherapycan be developed to produce safe and effective products and, if so,whether its vaccine products will be commercially accepted andprofitable, the expenses, delays and uncertainties and complicationstypically encountered by development stage biopharmaceuticalbusinesses, financial and development obligations under licensearrangements in order to protect its rights to its products andtechnologies, obtaining and protecting new intellectual propertyrights and avoiding infringement to third parties and their dependenceon manufacturing by third parties.

Many factors, both known andunknown, could cause actual results, performance or achievements to bematerially different from the results, performance or achievementsthat are or may be expressed or implied by such forward-lookingstatements and the parties have made assumptions and estimates basedon or related to many of these factors. Such factors include, withoutlimitation, future operations of the Company. BioVaxys does not assumeany obligation to update the forward-looking statements of beliefs,opinions, projections, or other factors, should they change, except asrequired by applicable securities laws.

The Canadian Securities Exchange has not reviewed, approved nordisapproved the contents of this news release and does not acceptresponsibility for the adequacy or accuracy of this newsrelease.

// NOT FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES //

Copyright (c) 2025 TheNewswire - All rights reserved.